MedTrace Logo

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

NCT06561620 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 592

Last updated 2024-08-22

No results posted yet for this study

Summary

To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).

Conditions

  • 3-year Disease-free Survival

Interventions

DRUG

Befotertinib

Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2027-05-01
Completion
2029-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06561620 on ClinicalTrials.gov